首页> 外文期刊>Autoimmunity >Autoimmunity and idiopathic dilated cardiomyopathy: where we stand?
【24h】

Autoimmunity and idiopathic dilated cardiomyopathy: where we stand?

机译:自身免疫和特发性扩张型心肌病:我们的立场是什么?

获取原文
获取原文并翻译 | 示例
           

摘要

Idiopathic dilated cardiomyopathy (DCM) with its heterogeneous phenotype and genotype remains one of the leading causes of severe heart failure particularly in the younger. Even in the elderly, it appears around 15% of heart failure is due to DCM. Despite great improvements in heart failure therapy, prognoses remains poor. One of the most important reasons is that the present heart failure management is aimed mostly at restoration of neurohormonal balance, rather than targeting primary causes of the disease. As a matter of fact, a substantial subgroup of DCM and chronic heart failure is accompanied by autoimmune mechanism, in particular a wide spectrum of autoantibodies. For almost two decades, the autoimmune hypothesis has been considered a "fairy tale". Today, we have better understanding of autoimmune mechanism in DCM. This focused issue is aimed to summarize what has happened in the last two decades in the context of basic understanding of underlying mechanisms and clinical relevance.
机译:具有异质表型和基因型的特发性扩张型心肌病(DCM)仍然是严重心力衰竭的主要原因之一,尤其是在年轻人中。即使在老年人中,也似乎有15%的心力衰竭是由于DCM引起的。尽管心力衰竭治疗有了很大的进步,但预后仍然很差。最重要的原因之一是当前的心力衰竭治疗主要针对恢复神经激素平衡,而不是针对疾病的主要病因。实际上,DCM和慢性心力衰竭的一个重要亚组伴随着自身免疫机制,尤其是多种自身抗体。近二十年来,自身免疫假说一直被认为是“童话”。今天,我们对DCM中的自身免疫机制有了更好的了解。本集中讨论的问题旨在总结在对基础机制和临床相关性的基本了解的背景下,过去二十年来发生的事情。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号